KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
16 juin 2021 08h00 HE
|
KBP BioSciences
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...
KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients
07 déc. 2020 08h00 HE
|
KBP BioSciences
KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to placebo Positive diastolic blood pressure (DBP) and Urine Albumin-to-Creatinine Ratio (UACR) Trends ...
KBP Biosciences Appoints Douglas Losordo Chief Medical Officer
18 nov. 2020 08h00 HE
|
KBP BioSciences
PRINCETON, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the...
KBP Biosciences to Present at Upcoming Virtual Investor Conferences
16 nov. 2020 08h00 HE
|
KBP BioSciences
PRINCETON, N.J., , Nov. 16, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the...
KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting
22 oct. 2020 16h30 HE
|
KBP BioSciences
PRINCETON, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences Holdings Limited (KBP Biosciences), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074
05 août 2020 08h00 HE
|
KBP BioSciences
KBP-5074 Being Evaluated for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) PatientsTop-Line Data on Track for Fourth Quarter of 2020 PRINCETON, N.J., Aug. 05,...
KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension
29 juin 2020 08h00 HE
|
KBP BioSciences
KBP-5074 is a highly-selective non-steroidal mineralocorticoid receptor antagonist with potentially reduced hyperkalemia riskArticle published online; to be included in July 2020 print edition of...
KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis
21 mai 2020 08h35 HE
|
KBP BioSciences
Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or without hemodialysisOverall drug exposure was significantly lower in hemodialyzed patients vs....
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074
20 mai 2020 08h00 HE
|
KBP BioSciences
KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) Patients Top Line Data...
KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii
28 avr. 2020 08h00 HE
|
KBP BioSciences
Potency demonstrated across geographically diverse strains including antibiotic-resistant isolates Data published online in Antimicrobial Agents and Chemotherapy PRINCETON, N.J., April 28, 2020 ...